Allan, J., Mulvey, E., Helbig, D., Malakhov, N., Chen, Z., Hobbie, B., Nazir, S., White, J., Grant, Z., Matejka, J., Morris, S., Bao, L., Martin, P., Furman, R. (2025). Zanubrutinib and venetoclax as initial therapy for CLL/SLL with obinutuzumab triplet consolidation in patients with detectable minimal residual disease (BruVenG).. Blood. https://doi.org/10.1182/blood-2025-3886